Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 22 EP applications Mark Hillier has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12706858

QUINOLINONE DERIVATIVES

IPC classification:
A61K 31/47, A61K 31/4709, A61P 3/10, A61P 9/10, A61P 25/16, A61P 25/28, C07D 215/20, C07D 215/36, C07D 401/04, C07D 401/10, C07D 401/14, C07D 409/14, C07D 413/04, C07D 413/14, C07D 417/04, C07D 417/10, C07D 417/14
Applicant:
GlaxoSmithKline LLC
Agent:
Mark Hillier, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP12738141

HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS

IPC classification:
A61K 31/505, A61P 35/00, C07D 403/12, C07D 491/10
Applicant:
Cellzome Ltd
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12762577

PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

IPC classification:
A61K 31/519, A61P 37/06, C07D 471/04, C07D 487/04
Applicant:
Cellzome Ltd
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11722343

PYRROLO [3, 2 -D]PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK

IPC classification:
A61K 31/519, A61P 3/04, A61P 3/10, A61P 9/00, A61P 9/10, A61P 35/00, C07D 487/04
Applicant:
GlaxoSmithKline LLC
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12800913

TRPV4 ANTAGONISTS

IPC classification:
A61K 31/422, A61P 9/04, C07D 413/08, C07D 413/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12814591

TRPV4 ANTAGONISTS

IPC classification:
C07D 263/52, C07D 419/14, C07D 498/00
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12806057

PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS

IPC classification:
A61K 31/506, A61P 35/00, A61P 37/00, C07D 403/14
Applicant:
Cellzome Ltd
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12797080

NOVEL COMPOUNDS

IPC classification:
A01N 43/42, A61K 31/437, A61P 25/28, C07D 401/00, C07D 471/04, C07D 519/00
Applicant:
GlaxoSmithKline Intellectual Property Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11714581

PYRAZOLE COMPOUNDS AS JAK INHIBITORS

IPC classification:
A61K 31/519, A61P 29/00, A61P 35/00, C07D 487/04
Applicant:
Cellzome Ltd
Agent:
Edwin Büchel, Isenbruck Bösl Hörschler LLP
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13738099

THERAPEUTIC USES

IPC classification:
A61K 31/4174, A61K 31/4245, A61K 31/445, A61K 31/4545, A61K 31/501, A61K 31/55, A61P 25/00, C07D 211/14, C07D 223/16, C07D 233/64, C07D 237/14, C07D 317/48, C07D 401/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12801296

TRPV4 ANTAGONISTS

IPC classification:
A61K 31/423, A61P 9/10, C07D 413/08
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
PATENT GRANTED
EP12706859

1H-PYROLLO[3,2-d]PYRIMIDINEDIONE DERIVATIVES

IPC classification:
A61K 31/519, A61P 3/00, A61P 9/00, A61P 35/00, C07D 487/04
Applicant:
GlaxoSmithKline LLC
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13724816

HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS

IPC classification:
A61K 31/505, A61P 37/00, C07D 401/14, C07D 403/12, C07D 405/14, C07D 413/14
Applicant:
Cellzome Ltd
Agent:
Mark Hillier, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP15166109

PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)

IPC classification:
A61K 31/47, A61P 37/00, C07D 401/12, C07D 403/12
Applicant:
Glaxo Group Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP11757574

2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS

IPC classification:
A61K 31/42, A61K 31/4406, A61K 31/4439, A61K 31/4545, A61K 31/501, A61K 31/5377, C07C 235/64, C07D 213/75, C07D 231/12, C07D 237/22, C07D 261/14, C07D 295/192, C07D 401/12, C07D 403/12, C07D 413/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11706815

Morpholino substituted urea derivatives as mtor inhibitors

IPC classification:
A61K 31/5377, A61P 37/00, C07D 239/42, C07D 401/04, C07D 413/04, C07D 413/14, C07D 498/08
Applicant:
Cellzome Ltd
Agent:
Edwin Büchel, Isenbruck Bösl Hörschler LLP
Agent:
Mark Hillier, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11760129

TRPV4 ANTAGONISTS

IPC classification:
A61K 31/47, A61P 9/00, A61P 13/10, C07D 401/06, C07D 401/14
Applicant:
GlaxoSmithKline LLC
Agent:
Mark Hillier, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14818951

3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS

IPC classification:
A61K 31/423, A61K 31/4439, A61K 31/501, A61K 31/506, A61P 25/00, C07D 263/58, C07D 413/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
The patent has been granted
EP15743797

COMPOUNDS

IPC classification:
A61K 31/519, A61P 25/16, C07D 487/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15743645

COMPOUNDS

IPC classification:
A61K 31/437, A61K 31/4375, A61P 25/16, C07D 403/00, C07D 403/02, C07D 487/00, C07D 487/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15720312

A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE

IPC classification:
A61K 31/4025, A61P 25/28, C07D 405/14
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15810681

3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS

IPC classification:
A61K 31/423, A61K 31/4439, A61K 31/501, A61K 31/506, A61P 1/00, A61P 25/00, A61P 31/00, C07D 413/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature